1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population
description
Transcript of 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population
![Page 1: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/1.jpg)
![Page 2: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/2.jpg)
![Page 3: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/3.jpg)
• 1st described 1967 (Ashbaugh et al)
• Incidence 1.5 -7.5/ 100000 population
• 28 day mortality 25 – 30%1
• Diagnosis clinical
![Page 4: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/4.jpg)
![Page 5: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/5.jpg)
![Page 6: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/6.jpg)
![Page 7: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/7.jpg)
Differential diagnosis
• LVF• Fluid overload• Mitral stenosis• Lymphangitis
carcinomatosis• Interstitial lung
disease
![Page 8: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/8.jpg)
![Page 9: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/9.jpg)
![Page 10: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/10.jpg)
![Page 11: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/11.jpg)
![Page 12: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/12.jpg)
![Page 13: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/13.jpg)
![Page 14: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/14.jpg)
![Page 15: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/15.jpg)
![Page 16: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/16.jpg)
![Page 17: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/17.jpg)
![Page 18: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/18.jpg)
Alveolar Damage
Capillary Damage
Leakage Oedema
Fluid
InflammatoryCellular Infiltrates
V/Q Mismatch
Atelectasis
↓ThoracicCompliance
↑Dead Space
Hypoxic Vasoconstriction
Hypoxia
![Page 19: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/19.jpg)
![Page 20: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/20.jpg)
![Page 21: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/21.jpg)
![Page 22: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/22.jpg)
![Page 23: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/23.jpg)
![Page 24: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/24.jpg)
Long Term
• Chronic Respiratory Disease
• Muscle Fatigue
• Muscle Wasting
• Weakness
![Page 25: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/25.jpg)
Symptoms and Signs+• Rapid onset of profound dyspnea, usually 12–48 hours after the initiating event• Labored breathing and tachypnea, with crackles on examination• Marked hypoxemia refractory to supplemental oxygen • Multiple-organ failure is seen in many patients
![Page 26: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/26.jpg)
![Page 27: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/27.jpg)
Differential Diagnosis Because ARDS is a syndrome, the concept of differential diagnosis applies only in considering the precipitating illness or injury• Cardiogenic (hydrostatic) pulmonary edema• Pneumonia• Aspiration• Diffuse alveolar hemorrhage• Acute interstitial pneumonitis• Acute eosinophilic pneumonia• Acute hypersensitivity pneumonitis• Cryptogenic organizing pneumonia• Pulmonary contusion• Drug-induced lung disease
![Page 28: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/28.jpg)
Diagnosis Laboratory Tests• Tests to identify the systemic or pulmonary causes of ARDS are indicated
Imaging Studies Chest radiograph shows diffuse or patchy bilateral opacities that rapidly become confluent Air bronchograms are seen in 80% of cases Features of heart failure (pleural effusions, cardiomegaly, venous engorgement in upper lung zones, indistinct blood vessels) are absent
Diagnostic Procedures When indicated to exclude cardiogenic pulmonary edema, pulmonary artery catheterization will demonstrate pulmonary arterial wedge pressures ≤ 18 mm Hg
![Page 29: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/29.jpg)
![Page 30: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/30.jpg)
![Page 31: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/31.jpg)
![Page 32: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/32.jpg)
![Page 33: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/33.jpg)
![Page 34: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/34.jpg)
![Page 35: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/35.jpg)
![Page 36: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/36.jpg)
![Page 37: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/37.jpg)
Noninvasive sampling • Trakeobronchial aspiration • mini-bronkoalveolar lavage Mikroskobik analiz (Gram boyaması , sitoloji )Mikrobiyolojik kültür
• Can be diagnostic for pnomonia , cancer , inflamatuar conditions
![Page 38: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/38.jpg)
Fleksibl bronkoskopi • Mikroskobik analiz ve mikrobiyolojik kültür • Non invaziv tetkikler başarısız ise • Non invaziv örnekleme mümkün olmuyor ise
• Havayollarında kırmızı taze kan, BAL sıvısında eritrosit artışı, hemosiderin-laden makrofajlar : diffüz alveolar hemoraji
• BAL sıvısında eozinofil sayısında artış : idiyopatik akut eozinofilik pnomoni
• Yiyecek partikülleri : aspirasyon pnomonisi
![Page 39: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/39.jpg)
Ekokardiyografi • Klinik ve BNP ile kardiyojenik pulmoner ödem tanısı
dışlanamazsa transtorasik eko kullanılır• Şiddetli aort yada mitral kapak disfonksiyonu Şiddetli diastolik disfonksiyon Sol ventrikül EF de belirgin azalma
• Kardiyojenik pulmoner ödemi destekler • Bazı ARDS tetikleyicileri ( septik şok ) şiddetli
kardiyomyopatiye yol açabilir ve ARDS ile birlikte bulunabilir [1,2].
1 Bouhemad B, Crit Care Med 2009; 37:441.2 Landesberg G, Eur Heart J 2012; 33:895.
![Page 40: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/40.jpg)
Akciğer biyopsisi • Akut hipoksemik solunum yetersizliğinin diğer nedenleri
dışlanamıyorsa cerrahi biyopsinin yeri vardır [1,2]. • Major komplikasyon oranı %7 dir. Biyopsiye atfedilen ölüm yoktur.
Komplikasyon oranı % 39 olmasına rağmen çoğu tolere edilmektedir (persistan hava kaçağı).
• Biyopsi sonucuna göre hastaların % 60 ına spesifik tedavi yapmak mümkün olmuştur. % 37 hastada gereksiz tedaviler kesilmiştir.
• Hedefev yönelik tedavi ve prognoz öngörüsü bakımından biyopsi gereklidir.
Örnekler: • Kriptojenik organize pnomoni • Akut fungal infeksiyon • Kronik interstisyen akciğer hastalşığı, vaskülitin alevlenmesi • Dissemine kanser
Patel SR, Chest 2004; 125:197.Papazian L, Anesthesiology 1998; 88:935.
![Page 41: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/41.jpg)
DIFFERENTIAL DIAGNOSIS
Cardiogenic pulmonary edema • is usually due to left ventricular systolic or diastolic dysfunction• may also be due to fluid overload, severe hypertension, renal artery
stenosis, or severe renal disease.• Its presentation is nearly identical to ARDS• except there may be evidence of cardiac dysfunction (S3 or S4 gallop, new
or changed murmur), • elevated right-sided filling pressures (elevated jugular venous pressure), • related radiographic abnormalities (pulmonary venous congestion, Kerley B
lines, cardiomegaly, and pleural effusions).
Distinguishing cardiogenic pulmonary edema from ARDS can be aided by • measurement of a BNP• echocardiography, • right heart catheterization.
![Page 42: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/42.jpg)
An acute exacerbation of idiopathic pulmonary fibrosis or other chronic interstitial lung diseases
• Like ARDS, the pathological findings are dominated by diffuse alveolar damage, but the prognosis is substantially worse.
• This diagnostic possibility is easily overlooked in patients whose underlying interstitial lung disease is unknown or mild or moderate in severity.
• The diagnosis is suggested by careful review of previous chest radiographic images, by discovery of subpleural reticulocytic changes intermixed with alveolar opacities on a chest CT scan obtained shortly after onset of ARDS, or by surgical lung biopsy
![Page 43: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/43.jpg)
Diffuse alveolar hemorrhage • May be associated with a large, otherwise unexplained
drop in the hemoglobin concentration and hematocrit.• While hemoptysis may be minimal or absent,
bronchoscopy often reveals frothy bloody secretions throughout the airways and invariably detects an increasing amount of red blood cells in serial bronchoalveolar lavage specimens.
• The recovery of hemosiderin-laden macrophages from bronchoalveolar lavage fluid is strongly suggestive of diffuse alveolar hemorrhage.
![Page 44: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/44.jpg)
Idiopathic acute eosinophilic pneumonia (IAEP)
Occurs in previously healthy individuals and is characterized by cough, fever, dyspnea, and sometimes chest pain. Bronchoalveolar lavage specimens always contain a large number of eosinophils, typically 35 to 55 percent of all recovered cells . Peripheral eosinophil may or may not be present
![Page 45: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/45.jpg)
Cryptogenic organizing pneumonia (COP) • often mimics community-acquired pneumonia with an onset that is
heralded by a flu-like illness with fever, malaise, fatigue, and cough. • The most common features a persistent nonproductive cough,
dyspnea with exertion, and weight loss. • BAL usually contains a smaller proportion of macrophages and
higher proportions of lymphocytes, neutrophils, and eosinophils than healthy patients.
• This "mixed pattern" of increased cellularity is thought to be characteristic of COP.
• The diagnosis is made by ruling out infectious causes of pneumonia and documenting typical pathologic changes in tissue obtained by open lung biopsy.
![Page 46: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/46.jpg)
Acute interstitial pneumonia (Hamman-Rich syndrome) • is a rare and fulminant form of diffuse lung injury that
has a presentation similar to ARDS.• Many people consider acute interstitial pneumonia a
subset of idiopathic ARDS since its clinical manifestations are similar and both demonstrate diffuse alveolar damage on histopathology.
• The distinguishing characteristic is that ARDS is often associated with a known risk factor, whereas acute interstitial pneumonia is not.
![Page 47: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/47.jpg)
Cancer • can disseminate through the lungs so rapidly that
the ensuing respiratory failure may be mistaken for ARDS.
• This is most often due to lymphoma or acute leukemia, but lymphangitic spread of solid tumors occasionally behaves this way.
• Cytological preparation of bronchoscopic specimens (eg, brushings, lavage) may reveal malignant cells.
![Page 48: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/48.jpg)
![Page 49: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/49.jpg)
Treatment Medications• Medications directed at the underlying cause of ARDS are indicated• Intravascular volume should be maintained at the lowest level required to maintain adequate cardiac output• Diuretics may be needed to reduce pulmonary capillary wedge pressure and improve oxygenation• Cardiac output that falls when PEEP is used may be improved by reducing the level of PEEP or by the judicious use of inotropic drugs (eg, norepinephrine)• Achieving supranormal oxygen delivery through the use of inotropes and blood transfusion is not clinically useful and may be harmful• Sedatives, analgesics, and antipyretics may be used to decrease oxygen consumption• Systemic corticosteroids have not been shown to reliably improve outcomes
![Page 50: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/50.jpg)
Therapeutic Procedures
• Intubation and mechanical ventilation are usually required to treat hypoxemia• Use the lowest levels of PEEP and Fio2 needed to maintain Pao2 > 55 mm Hg (7.13 kPa) or the Sao2 above 88%• Mechanical ventilation with small tidal volumes (6 mL/kg of ideal body weight) has been shown to reduce mortality by 10% in a multicenter trial• PEEP may be increased as long as cardiac output and oxygen delivery are not impaired and pulmonary pressures are not excessive• Prone positioning may improve oxygenation in selected patients
![Page 51: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/51.jpg)
![Page 52: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/52.jpg)
![Page 53: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/53.jpg)
![Page 54: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/54.jpg)
![Page 55: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/55.jpg)
![Page 56: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/56.jpg)
![Page 57: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/57.jpg)
![Page 58: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/58.jpg)
Supine Ventilation
• ± 40% lung volume under lung, especially patients with large hearts
![Page 59: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/59.jpg)
Prone Ventilation
![Page 60: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/60.jpg)
![Page 61: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/61.jpg)
![Page 62: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/62.jpg)
• Theoretical use to ↓inflammatory response associated with ARDS
• 2006 study• No ↓60 day mortality (28.6%
vs 29.2% p= 0.10)• Use of steroids 14+ days post
onset: ↑ mortality• ↓ need for vasopressors• ↑ ventilator and shock free
days• ↑ neuromuscular weakness• Short term improvement in
oxygenation
![Page 63: 1 st described 1967 ( Ashbaugh et al) Incidence 1.5 -7.5/ 100000 population](https://reader036.fdocuments.us/reader036/viewer/2022062309/56813e30550346895da8123a/html5/thumbnails/63.jpg)